Navigation Links
Cobalis Expects to Report Phase III Top-Line Results in May

IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced it has been informed by its independent contract research organization that it would need more time to combine Cobalis' three locked data bases into a single database before un-blinding and conducting the statistical analysis required to generate top-line results for Cobalis' twin pivotal Phase III Clinical Trials of PreHistin(TM) in seasonal allergic rhinitis. The Company anticipates reporting its top-line results later in May.

About Cobalis Corp.

Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. Cobalis plans to seek FDA approval to market PreHistin over-the-counter in the US. For further information, visit www.cobalis.com

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and un
'"/>




Page: 1 2

Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cobalis Expects Report Phase III Top Line Results May
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... Aug. 27, 2015  Lightwave Logic, Inc. (OTCQB: ... of Next Generation Photonic Devices and Non-Linear ... high speed fiber-optic data communications and optical computing, ... has been appointed to the Company,s Board of ... field of optoelectronics is widely recognized with wide-ranging ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... 3, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect ... principal amount of senior unsecured notes (the "Notes"). ... Securities Act of 1933, as amended (the "Securities Act"), ...
... Feb. 3, 2011 Unilife Corporation ("Unilife" or the "Company") ... it has appointed Dr. Ramin Mojdeh, formerly Vice President and ... and Worldwide Vice President of Research and Development, BD Medical, ... effective February 7, 2011. Dr. Mojdeh comes ...
Cached Medicine Technology:Valeant Launches Senior Notes Offering 2Valeant Launches Senior Notes Offering 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 2Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 3Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 4Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer 5
(Date:8/27/2015)... Florida (PRWEB) , ... August 28, 2015 , ... This ... to ensure that patients are always scheduled for the next visit, their authorizations are ... here . , According to Jason Barnes, COO for Genesis Chiropractic Software, growing ...
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some ... months later, relapsing and returning again, all at great cost to them and their ... living homes or soon after leaving facilities who claim to have given addicts tools ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published August ... new guidelines to educate doctors and patients on the best practices for type 2 ... in 2007, so the new version is taking into account nearly a decade of ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... enter the exploding legal marijuana industry with the launch of its Doobster platform, ... legal marijuana to order products from their smart phones and tablets. Well, ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... The ... will now be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. ... chin, Kybella provides permanent results without surgery. Dr. Kulak is the only Board ...
Breaking Medicine News(10 mins):Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... Network is very near to achieving one of today’s Science ... health conditions.// ,As well as from the UGR, ... and Reus also took part in this study, concluding that ... small amounts by human beings and present in many types ...
... medical disorder in pregnancy, adversely affecting maternal and ... control and treatment of anemia during pregnancy, the ... majority of women present late. ... consequences that extend over generations. Girls born underweight ...
... Dev has launched a seven-day camp in this Taj Mahal ... other licentious activities.// ,Ram Dev, who enjoys wide following ... education being given to the young. ,'A balanced ... he said. ,Later speaking to journalists, Ram Dev ...
... and healthcare inequalities may have the most significant ... (CRC) between African// Americans and Caucasians, according to ... 2007 issue of CANCER, a peer-reviewed journal of ... from published studies demonstrated that when socioeconomic factors ...
... a handful of concerned citizens. Delhi, burning under the scorching ... voice on various issues that are pricking our fragile ecosystem. ... said Ravi Aggarwal of Toxics Link, an environmental NGO. 'The ... name of development needs to be addressed immediately and a ...
... electronic biometric attendance system to check late-coming teachers.// ... schools, but later will be extended to all schools in ... of Jaipur and five schools of Dausa. ,'Some ... be used on an experimental basis,' said Vasudev Devnani, Rajasthan's ...
Cached Medicine News:Health News:High Melatonin can Help Delay Ageing 2Health News:Social Factors Not Genetics Drive Racial Disparities in Colorectal Cancer Survival 2Health News:Earth Day Celebrated With Hopes of a Greener Tomorrow 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
Profix total knee system is intended for cemented use only....
Medicine Products: